

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **SB 63** SLS 202ES 154

Bill Text Version: **ORIGINAL**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

Date: October 7, 2020 1:11 PM	Author: BARROW
Dept./Agy.: Board of Pharmacy	Analyst: Shawn Hotstream
Subject: pharmacist	

PHARMACISTS OR GF EX See Note Page 1 of 1
Provides for pharmacists to test or screen and initiate therapy for certain health conditions including COVID-19. (See CA3s19) (Item #40)

Proposed law provides the board of pharmacy to establish a written statewide protocol for pharmacists to test or screen and initiate treatment or therapy for certain qualified health conditions. The list of qualified conditions for testing, screening, and treatment or therapy shall include Influenza, Streptococcal infections, COVID-19, HIV, and any other health condition approved by the board. Treatment or therapy for HIV may include an HIV Pre-Exposure prophylaxis, also known as PrEP, or an HIV Post-Exposure Prophylaxis, also known as PEP. Proposed law provides that a pharmacist who tests or screens for and initiates treatment or therapy for a health condition under this measure may use any test that guides diagnosis or clinical decision making which the Centers for Medicare and Medicaid Services (CMS) has determined qualifies for a waiver in accordance with the federal Clinical Laboratory Improvement Amendments of 1988 or any established screening procedure that can safely be performed by a pharmacist under the pharmacist's professional license.

EXPENDITURES	2020-21	2021-22	2022-23	2023-24	2024-25	5 -YEAR TOTAL
State Gen. Fd.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Agy. Self-Gen.	INCREASE	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total						
REVENUES	2020-21	2021-22	2022-23	2023-24	2024-25	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

The board of pharmacy anticipates a minimal fiscal impact to develop written protocols for pharmacists for their use in the testing/screening for certain health conditions as well as their initiation of treatment or therapy for those health conditions. Costs are associated with board member per diem and travel (\$2,000) to meet with various pharmacy practitioners and medical consultants to develop protocols. The Louisiana Department of Health indicates no anticipated costs associated with proposed legislation. Note: The LFO has asked the department if a pharmacist providing screening, testing, and initiation of treatment under this measure would be considered billable services for Medicaid eligibles.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Christopher A. Keaton
Legislative Fiscal Officer